Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK
Tasneem Pirani(King's College Hospital NHS Foundation Trust), Victoria Metaxa(Apple (Israel)), Amrith Mathew(University Hospitals Birmingham NHS Foundation Trust), Rohit Saha(King's College Hospital NHS Foundation Trust), David Brealey(UCL Biomedical Research Centre), Mansoor N. Bangash, Suzanne C. O’Neill(Georgetown University), Jenny Le(University of the West of England), C. Wright(Queen Elizabeth University Hospital), Ryan Low(University College Hospital), Anne‐Louise Latif(Queen Elizabeth University Hospital), Vidya Kasipandian, Neeraj Singh(Willis-Knighton Cancer Center), Anthony Wilson(Manchester Royal Infirmary), David Irvine(NHS Greater Glasgow and Clyde), Shaman Jhanji(Royal Statistical Society)
Cited by 1
Related Papers
Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer Surgery
|Anesthesiology|2015|502
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
|The Lancet|2020|366
Diagnosis of severe respiratory infections in immunocompromised patients
|Intensive Care Medicine|2020|340
Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study
|Intensive Care Medicine|2017|318
Communication and Virtual Visiting for Families of Patients in Intensive Care during the COVID-19 Pandemic: A UK National Survey
|Annals of the American Thoracic Society|2021|224